In one patient who had the last dose of ofatumumab 24 days prior to COVID-19 symptoms but had paused ofatumumab for 28 weeks beforehand due to low IgM levels, SARS-CoV-2-antibody titers higher than 250 U/mL had been detected. The gene discussed is CD40LG; the disease is COVID-19.